Protein-Losing enteropathy after fontan operation

Congenital Heart Disease

Volumn 2, Issue 5, 2007, Pages 288-300

  Rychik, Jack ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Fontan Operation; Protein Losing Enteropathy; Single Ventricle

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; BUDESONIDE; CARVEDILOL; CORTICOSTEROID; ENOXAPARIN; FUROSEMIDE; GLYCOSAMINOGLYCAN; HEPARIN; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; MEDIUM CHAIN TRIACYLGLYCEROL; OCTREOTIDE; PREDNISONE; SILDENAFIL; SPIRONOLACTONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ADRENAL SUPPRESSION; ANTIDIURESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DEMINERALIZATION; CLINICAL FEATURE; DEHYDRATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; ELECTROLYTE DISTURBANCE; FECES LEVEL; FENESTRATION; FONTAN PROCEDURE; FORWARD HEART FAILURE; GYNECOMASTIA; HEART DISEASE; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPROTEINEMIA; HYPOTENSION; INFLAMMATION; LIPID DIET; MESENTERIC ARTERY; MOON FACE; NUTRITIONAL SUPPORT; OSTEOPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; SIDE EFFECT; STRESS FRACTURE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; VASODILATATION;

CARDIAC OUTPUT; CELL MEMBRANE; ENTEROCYTES; FONTAN PROCEDURE; GLYCOSAMINOGLYCANS; HEMODYNAMICS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PROTEIN-LOSING ENTEROPATHIES; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE;

EID: 34548778629     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2007.00116.x     Document Type: Article

References (57)

1. Stamm C, Friehs I, Mayer JE, et al. Long-term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg. 2001;121:28-41.
2. Alphonso N, Baghai M, Sundar P, Tulloh R, Austin C, Anderson D. Intermediate-term outcome following the fontan operation: A survival, functional and risk-factor analysis. Eur J Cardiothorac Surg. 2005;28:529-535.
3. Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M, Breymann T. Clinical outcome of patients 20 years after Fontan operation - effect of fenestration on late morbidity. Eur J Cardiothorac Surg. 2006;30:923-929.
4. Mitchell ME, Ittenbach RF, Gaynor JW, Wernovsky G, Nicolson S, Spray TL. Intermediate outcomes after the Fontan procedure in the current era. J Thorac Cardiovasc Surg. 2006;131:172-180.
5. Fontan F, Kirklin JW, Fernandez G, et al. Outcome after a "perfect" Fontan operation. Circulation. 1990;81:1520-1536.
6. Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ. Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology. 1981;81:777-780.
7. Fujii T, Shimizu T, Takahashi K, et al. Fecal alpha1-antitrypsin concentrations as a measure of enteric protein loss after modified fontan operations. J Pediatr Gastroenterol Nutr. 2003;37:577-580.
8. Bartz PJ, Driscoll DJ, Dearani JA, et al. Early and late results of the modified fontan operation for heterotaxy syndrome 30 years of experience in 142 patients. J Am Coll Cardiol. 2006;48:2301-2305.
9. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: An international multicenter study. PLE Study Group. J Thorac Cardiovasc Surg. 1998;115:1063-1073.
10. Earing MG, Cetta F, Driscoll DJ, et al. Long-term results of the Fontan operation for double-inlet left ventricle. Am J Cardiol. 2005;96:291-298.
11. Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 1996;112:672-680.
12. Thorne SA, Hooper J, Kemp M, Somerville J. Gastro-intestinal protein loss in late survivors of Fontan surgery and other congenital heart disease. Eur Heart J. 1998;19:514-520.
13. Coon PD, Rychik J, Novello RT, Ro PS, Gaynor JW, Spray TL. Thrombus formation after the Fontan operation. Ann Thorac Surg. 2001;71:1990-1994.
14. Cohen MI, Bush DM, Ferry RJ Jr, et al. Somatic growth failure after the Fontan operation. Cardiol Young. 2000;10:447-457.
15. Saitoh O, Matsumoto H, Sugimori K, et al. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and alpha-1-antitrypsin levels in patients with colorectal diseases. Digestion. 1995;56:67-75.
16. Perednia DA, Curosh NA. Lupus-associated protein-losing enteropathy. Arch Intern Med. 1990;150:1806-1810.
17. Salvia G, Cascioli CF, Ciccimarra F, Terrin G, Cucchiara S. A case of protein-losing enteropathy caused by intestinal lymphangiectasia in a preterm infant. Pediatrics. 2001;107:416-417.
18. Nelson DL, Blaese RM, Strober W, Bruce R, Waldmann TA. Constrictive pericarditis, intestinal lymphangiectasia, and reversible immunologic deficiency. J Pediatr. 1975;86:548-554.
19. Strober W, Cohen LS, Waldmann TA, Braunwald E. Tricuspid regurgitation. A newly recognized cause of protein-losing enteropathy, lymphocytopenia and immunologic deficiency. Am J Med. 1968;44:842-850.
20. Moodie DS, Feldt RH, Wallace RB. Transient protein-losing enteropathy secondary to elevated caval pressures and caval obstruction after the Mustard procedure. J Thorac Cardiovasc Surg. 1976;72:379-382.
21. Crupi G, Locatelli G, Tiraboschi R, Villani M, De Tommasi M, Parenzan L. Protein-losing enteropathy after Fontan operation for tricuspid atresia (imperforate tricuspid valve). Thorac Cardiovasc Surg. 1980;28:359-363.
22. Senzaki H, Masutani S, Kobayashi J, et al. Ventricular afterload and ventricular work in fontan circulation: Comparison with normal two-ventricle circulation and single-ventricle circulation with blalock-taussig shunts. Circulation. 2002;105:2885-2892.
23. Mahle WT, Todd K, Fyfe DA. Endothelial function following the Fontan operation. Am J Cardiol. 2003;91:1286-1288.
24. Szabo G, Buhmann V, Graf A, et al. Ventricular energetics after the Fontan operation: Contractility-afterload mismatch. J Thorac Cardiovasc Surg. 2003;125:1061-1069.
25. Rychik J, Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol. 2002;90:672-674.
26. Mertens L, Dumoulin M, Gewillig M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Br Heart J. 1994;72:591-592.
27. Rychik J, Rome JJ, Jacobs ML. Late surgical fenestration for complications after the Fontan operation. Circulation. 1997;96:33-36.
28. Cohen MI, Rhodes LA, Wernovsky G, Gaynor JW, Spray TL, Rychik J. Atrial pacing: An alternative treatment for protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 2001;121:582-583.
29. Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac transplantation for failed Fontan: A multi-institutional study. Circulation. 2006;114:273-280.
30. Rothman A, Snyder J. Protein-losing enteropathy following the Fontan operation: Resolution with prednisone therapy. Am Heart J. 1991;121:618-619.
31. Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol. 1991;68:819-821.
32. Therrien J, Webb GD, Gatzoulis MA. Reversal of protein losing enteropathy with prednisone in adults with modified fontan operations: long term palliation or bridge to cardiac transplantation? Heart. 1999;82:241-243.
33. Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr. 1997;130:474-478.
34. Kelly AM, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease. Mayo Clin Proc. 1998;73:777-779.
35. Kouretas PC, Hannan RL, Kapur NK, et al. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: Role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol. 1998;30:2669-2682.
36. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: Potential therapeutic applications beyond anticoagulation. Adv Pharmacol. 1999;46:151-208.
37. Murch SH, Winyard PJ, Koletzko S, et al. Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Lancet. 1996;347:1299-1301.
38. Westphal V, Murch S, Kim S, et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am J Pathol. 2000;157:1917-1925.
39. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: Investigations into possible pathophysiologic mechanisms. Ann Thorac Surg. 2006;82:695-700.
40. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:3C-8C.
41. Bode L, Eklund EA, Murch S, Freeze HH. Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1015-G1023.
42. Bode L, Murch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem. 2006;281:7809-7815.
43. Bode L, Freeze HH. Applied glycoproteomics - approaches to study genetic-environmental collisions causing protein-losing enteropathy. Biochim Biophys Acta. 2006;1760:547-559.
44. Ishibashi N, Park IS, Takahashi Y, et al. Effectiveness of carvedilol for congestive heart failure that developed long after modified Fontan operation. Pediatr Cardiol. 2006;27:473-475.
45. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg. 2006;82:e39-e40.
46. Ringel RE, Peddy SB. Efect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol. 2003;91:1031-1032.
47. Thohan V, Torre-Amione G, Koerner MM. Aldosterone antagonism and congestive heart failure: A new look at an old therapy. Curr Opin Cardiol. 2004;19:301-308.
48. Vyas H, Driscoll DJ, Cabalka AK, Cetta F, Hagler DJ. Results of transcatheter Fontan fenestration to treat protein losing enteropathy. Catheter Cardiovasc Interv. 2007;69:584-589.
49. McKeage K, Goa KL. Budesonide (Entocort EC Capsules): A review of its therapeutic use in the management of active Crohn's disease in adults. Drugs. 2002;62:2263-2282.
50. Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet. 2004;43:803-821.
51. Lundin PD, Edsbacker S, Bergstrand M, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther. 2003;17:85-92.
52. Connor FL, Angelides S, Gibson M, et al. Successful resection of localized intestinal lymphangiectasia post-Fontan: Role of (99m) technetium-dextran scintigraphy. Pediatrics. 2003;112:e242-e247.
53. Sheikh AM, Tang AT, Roman K, et al. The failing Fontan circulation: successful conversion of atriopulmonary connections. J Thorac Cardiovasc Surg. 2004;128:60-66.
54. Mavroudis C, Deal BJ, Backer CL. The beneficial effects of total cavopulmonary conversion and arrhythmia surgery for the failed Fontan. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2002;5:12-24.
55. Gamba A, Merlo M, Fiocchi R, et al. Heart transplantation in patients with previous Fontan operations. J Thorac Cardiovasc Surg. 2004;127:555-562.
56. Holmgren D, Berggren H, Wåhlander H, Hallberg M, Myrdal U. Reversal of protein-losing enteropathy in a child with Fontan circulation is correlated with central venous pressure after heart transplantation. Pediatr Transplant. 2001;5:135-137.
57. Brancaccio G, Carotti A, D'Argenio P, Michielon G, Parisi F. Protein-losing enteropathy after Fontan surgery: Resolution after cardiac transplantation. J Heart Lung Transplant. 2003;22:484-486.